Drilldown: Medicines
Appearance
Medicines > onset
:
Estrogen suppression within days; clinical effect over months
or
Postprandial glucose effect within days; HbA1c by 12 weeks
& duration:
24 hours 
:
Estrogen suppression within days; clinical effect over months
or
Postprandial glucose effect within days; HbA1c by 12 weeks
& duration:
24 hours 
Use the filters below to narrow your results.
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (2) ·
[[:Category:Antineoplastics|Antineoplastic]] (1) ·
[[:Category:Aromatase_inhibitors|Aromatase inhibitor (non-steroidal)]] (1) ·
[[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (2) ·
[[:Category:Endocrine_therapy|Endocrine therapy]] (1) ·
[[:Category:Incretin_modulators|Incretin pathway modulator]] (2)
None (2) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
Contraindicated in pregnancy (only used in postmenopausal women); D class historically.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2)
Showing below up to 3 results in range #1 to #3.

